Ex-Receptos execs launch Gossamer with $100M

Gossamer Bio Inc. (San Diego, Calif.) launched with $100 million in financing, which includes seed funding from Omega Funds and an untranched series A round co-led by ARCH Venture Partners and Omega. Gossamer and Omega declined to say how much was raised in each round.

The newco said it will discover and develop "novel and differentiated" products to treat targeted patient populations with high unmet need. It will initially pursue indications in autoimmune disease and inflammation, with potential crossover into fibrosis and oncology...